
Endocrinologist

No OPD information available
Hormone Replacement Therapy (HRT)
Menopause
Abdominal Obesity Metabolic Syndrome
Diabetic Ketoacidosis
Gestational Diabetes
Ovarian Cysts
Polycystic Ovary Syndrome
Schizophrenia
Roisin N. Worsley is a female healthcare provider who helps patients with different health issues. She specializes in Hormone Replacement Therapy (HRT), Menopause, Abdominal Obesity Metabolic Syndrome, Diabetic Ketoacidosis, Gestational Diabetes, Ovarian Cysts, Polycystic Ovary Syndrome, and Schizophrenia.
Roisin N. Worsley uses her special skills to treat patients and make them feel better. She is good at talking to patients and making them feel comfortable. Patients trust her because she listens to them and explains things in a way they can understand.
Roisin N. Worsley keeps learning about new medical information and research to provide the best care for her patients. She stays updated with the latest knowledge to give the right treatments.
Roisin N. Worsley works well with other medical professionals. She values teamwork and collaboration to help patients get the best care possible. Her relationships with colleagues are important for providing good healthcare.
Roisin N. Worsley's work has positively impacted many patients' lives. She has helped patients improve their health and feel better. Her dedication to her patients has made a difference in their well-being.
One of Roisin N. Worsley's notable publications is about the study of antipsychotic medications in pregnancy. She also conducts clinical trials to investigate the efficacy of new drugs for patients with Borderline Personality Disorder.
In summary, Roisin N. Worsley is a caring healthcare provider who uses her skills and knowledge to help patients feel better. She stays updated with the latest medical information, works well with other professionals, and makes a positive impact on her patients' lives.
Enrollment Status: Recruiting
Published: November 18, 2024
Intervention Type: Other, Drug
Study Drug: N-Methyl-D-Aspartate (NMDA) Receptor Antagonist
Study Phase: Phase 2
